Advances in COVID-19 mRNA vaccine development
E Fang, X Liu, M Li, Z Zhang, L Song, B Zhu… - Signal transduction and …, 2022 - nature.com
To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
[HTML][HTML] Lipid nanoparticles for mRNA delivery
Messenger RNA (mRNA) has emerged as a new category of therapeutic agent to prevent
and treat various diseases. To function in vivo, mRNA requires safe, effective and stable …
and treat various diseases. To function in vivo, mRNA requires safe, effective and stable …
[HTML][HTML] mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability
A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they
have to be stored at (ultra) low temperatures. Understanding the root cause of the instability …
have to be stored at (ultra) low temperatures. Understanding the root cause of the instability …
Nanotechnology-based mRNA vaccines
Abstract mRNA vaccines have emerged as a revolutionary tool to generate rapid and
precise immune responses against infectious diseases and cancers. Compared with …
precise immune responses against infectious diseases and cancers. Compared with …
COVID-19 mRNA vaccines: Platforms and current developments
GT Szabó, AJ Mahiny, I Vlatkovic - Molecular Therapy, 2022 - cell.com
Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …
The global epidemic of the SARS-CoV-2 delta variant, key spike mutations and immune escape
D Tian, Y Sun, J Zhou, Q Ye - Frontiers in immunology, 2021 - frontiersin.org
During the COVID-19 pandemic, SARS-CoV-2 variants have emerged and spread
worldwide. The Delta (B. 1.617. 2) variant was first reported in India in October 2020 and …
worldwide. The Delta (B. 1.617. 2) variant was first reported in India in October 2020 and …
Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity
LB Rodda, PA Morawski, KB Pruner, ML Fahning… - Cell, 2022 - cell.com
Immune memory is tailored by cues that lymphocytes perceive during priming. The severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic created a situation in …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic created a situation in …
Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
I McDonald, SM Murray, CJ Reynolds, DM Altmann… - npj Vaccines, 2021 - nature.com
As SARS-CoV-2 vaccines are deployed worldwide, a comparative evaluation is important to
underpin decision-making. We here report a systematic literature review and meta-analysis …
underpin decision-making. We here report a systematic literature review and meta-analysis …
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
Summary The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-
binding domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient …
binding domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient …
[HTML][HTML] Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses
Various vaccine strategies have been proposed in response to the global COVID-19
pandemic, each with unique strategies for eliciting immune responses. Here, we developed …
pandemic, each with unique strategies for eliciting immune responses. Here, we developed …